Synthesis and anticonvulsant properties of a series of N-substituted 2-aza-spiro[4.5]decane-1,3-diones and 8-phenyl-2-aza-spiro[4.5]decane-1,3-diones

Acta Poloniae Pharmaceutica - Drug Research

Volumn 61, Issue 6, 2004, Pages 467-472

  Obniska, Jolanta ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

8 phenyl 2 aza spiro 4.5 decane 1,3 dione; Anticonvulsant activity; N phenyl substituted 2 aza spiro 4.5 decane 1,3 diones; Spirosuccinimides

Indexed keywords

2 AZASPIRO[4.5]DECANE 1,3 DIONE; 8 PHENYL 2 AZASPIRO[4.5]DECANE 1,3 DIONE; ANTICONVULSIVE AGENT; N (2 METHYLPHENYL) 2 AZASPIRO[4.5]DECANE 1,3 DIONE; N (3 METHYLPHENYL) 2 AZASPIRO[4.5]DECANE 1,3 DIONE; PENTETRAZOLE; SPIRO COMPOUND; SPIROSUCCINIMIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONVULSION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRIC SHOCK; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; SEIZURE;

ANIMALS; ANTICONVULSANTS; AZA COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MUSCULOSKELETAL EQUILIBRIUM; PENTYLENETETRAZOLE; SEIZURES; SPIRO COMPOUNDS;

EID: 13244253974     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Pastalos P. N.: Current Opinion in CPNS Investigational Drugs 5, 549 (1999).
2. Wong M. G., Defina J. A., Andrews P. R.: J. Med. Chem. 29, 562 (1986).
3. Puthucode R. N., Pugazhenthi U., Quail J. W., Stables J., Dimmock J. R.: Eur. J. Med. Chem. 33, 595 (1998).
4. Unverferth K., Engel J., Hofgen N., Rostock A., Gunther R., H.J. Lankau, Menzer M., Rolfs A., Liebscher J., Muller B, Hofmann H.J.: J. Med. Chem. 41, 63 (1998).
5. Vamecq J., Bac P., Herrenknecht Ch., Maurois P., Delcourt Ph., Stable J. P.: J. Med. Chem. 43, 131 (2000).
6. Scott K. R., Moore J. A., Zalucky T. B., Nicholson J. M., Lee M., Hinko Ch. N.: J. Med. Chem. 28, 413 (1985).
7. Edafiogho I. O., Scott K. R., Moore J. A., Farrar V. A., Nicholson J. M.: J. Med. Chem. 34, 387 (1991).
8. Alexander M. S., Stables J. P., Ciechanowicz-Rutkowska M., Hursthouse M. B., Hibbs D. E., Edafiogho I. O., Moore V. A., Scott K. R.: Eur. J. Med. Chem. 31, 787 (1996).
9. Obniska J., Kulig K., Zejc A.: Acta Polon Pharm-Drug Research 55, 223 (1998).
10. Obniska J., Zejc A., Karolak-Wojciechowska J.: Il Farmaco, 54, 423 (1999).
11. Obniska J., Zejc A., Zagórska A.: Acta Polon. Pharm.-Drug Res. 59, 209 (2002).
12. Obniska J., Zagórska A.: Il Farmaco 58, 1227 (2003).
13. Karolak-Wojciechowska J., Błaszczyk M., Kwiatkowski W., Obniska J., Zejc A.: J. Chem. Crystal. 27, 5, 297 (1997).
14. Faust J. A., Jules L. H., Lim Yee, Sahyun M.: J. Am. Pharm. Assoc. 46, 118 (1957).
15. El-Telbany F. A., Ghoneim K. M., Khalifa M.: J. Pharm. Belg. 34, 4, 403 (1976).
16. Krall R. L., Penry J. K., White B. G., Kupferberg H. J., Swinyard E. A.: Epilepsia 19, 409 (1978).
17. Kupferberg H. J.: Epilepsia 30 (Suppl.), 51 (1989).